Proroxan

Proroxan (INN; also known as pyrroxane and pirroksan) is a pharmaceutical drug used as an antihypertensive and in the treatment of Ménière’s disease, motion sickness, and allergic dermatitis.[1][2]

Proroxan
Clinical data
Other namesPyrroxane, Pirroksan
Legal status
Legal status
  • Rx in Russia
Identifiers
IUPAC name
  • 1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-(3-phenylpyrrolidin-1-yl)propan-1-one
CAS Number
PubChem CID
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H23NO3
Molar mass337.419 g·mol−1
3D model (JSmol)
SMILES
  • C1CN(CC1C2=CC=CC=C2)CCC(=O)C3=CC4=C(C=C3)OCCO4
InChI
  • InChI=1S/C21H23NO3/c23-19(17-6-7-20-21(14-17)25-13-12-24-20)9-11-22-10-8-18(15-22)16-4-2-1-3-5-16/h1-7,14,18H,8-13,15H2
  • Key:GZIISXIDAZYOLI-UHFFFAOYSA-N

Proroxan is a non-selective alpha-blocker (α-adrenoreceptor antagonist).[1]

Proroxan was developed in the 1970s at the Institute of Toxicology of the USSR Ministry of Health[3] and today is primarily used in Russia. Though originally developed as an antihypertensive, its use can lead to a decrease in alcohol and drug consumption. Currently proroxan is used almost exclusively in psychiatry, narcology, and neurology.[3]

References
  1. "Proroxan hydrochloride". Inxight Drugs. National Institutes of Health.
  2. "ПРОРОКСАН (PROROXAN) ОПИСАНИЕ". vidal.ru.
  3. Shabanov PD (2020). "Clinical pharmacology of pyrroxane (proroxane)". Reviews on Clinical Pharmacology and Drug Therapy (in Russian). 18 (4): 335–350. doi:10.17816/RCF184335-350. S2CID 234440112.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.